Aurantio-obtusin
CAS No. 67979-25-3
Aurantio-obtusin ( —— )
产品货号. M18988 CAS No. 67979-25-3
Aurantio-obtusin 是一种有前途的天然来源的骨合成代谢化合物,在预防骨质疏松症和其他代谢性骨疾病方面具有潜在的治疗应用。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1050 | 有现货 |
|
| 10MG | ¥1782 | 有现货 |
|
| 25MG | ¥3087 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Aurantio-obtusin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Aurantio-obtusin 是一种有前途的天然来源的骨合成代谢化合物,在预防骨质疏松症和其他代谢性骨疾病方面具有潜在的治疗应用。
-
产品描述Biotransformation of glucoAurantio-obtusin towards Aurantio-obtusin increased the toxicity of irinotecan through increased inhibition of SN-38 glucuronidation. Aurantio-obtusin, stimulated chemotactic migration of MC3T3-E1 osteoblast cells in a concentration-dependent manner. Besides migration, the compound stimulated osteoblast differentiation and mineralization. Aurantio-obtusin is a promising osteoanabolic compound of natural origin with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases.
-
体外实验——
-
体内实验Animal Model:C57BL/6J mice model Dosage:5 mg/kg, 10 mg/kg, 15 mg/kg Administration:Oral gavage (p.o.), feeding with HFSW diet for 4 weeks then giving different dose of Aurantio-obtusin for another 4 weeks. Result:Decreased the levels of TG and TC in liver and TG, ALT and AST in serum induced by HSFW.Reduced the number and size of fat droplets in liver cells.Significantly increased AMPK phosphorylation in HFSW-induced mice.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域Others-Field
-
适应症——
化学信息
-
CAS Number67979-25-3
-
分子量330.29
-
分子式C17H14O7
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 25 mg/mL (75.69 mM)
-
SMILESCC1=C(C(=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)OC)O)OC)O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
6-Fluoro-12-benzoiso...
中间体。
-
Ladiratuzumab
Ladiratuzumab (hLIV22) 是一种抗 LIV-1/ZIP6 的人源化单克隆抗体。Ladiratuzumab 与微管干扰剂 MMAE (HY-15162) 偶联,能够合成一种抗体-活性分子偶联物 (ADC) SGN-LIV1A。Ladiratuzumab 可用于乳腺癌的研究。
-
BMS-P5 free base
BMS-P5 游离碱是一种具有口服活性的特异性肽基精氨酸脱亚胺酶 4 (PAD4) 抑制剂。 BMS-P5 阻止中性粒细胞胞外陷阱的形成并延缓多发性骨髓瘤的进展。
021-51111890
购物车()
sales@molnova.cn

